ReviewJournal of the National Cancer Center2025
Revealing the landscape of targeting mitochondrial functions and behaviors to overcome cancer chemoresistance.
Review in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nano-hydrogel-based delivery system for dihydroartemisinin to enhance cuproptosis and synergize with anti-PD-1 therapy in triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
- TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression.Clinical and experimental medicine · 2026Article
- High matrix stiffness triggers the YAP-OPA1-TET1/3 loop to drive chemoresistance via enhanced nuclear-mitochondrial communication.iScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rapid progression of chemotherapies, the occurrence of chemoresistance is becoming a major obstacle in contemporary cancer treatment. As essential organelles, mitochondria perform diverse functions to provide ATP and various intermediates to modulate biosynthetic and bioenergetic processes, which are indispensable to cell survival. Recently, mitochondria have increasingly intrigued researchers for their unique influence on chemoresistance. This review explores the intricate relationship between mitochondria and chemoresistance. We delve into the complex roles that mitochondria play in chemoresistance, focusing on the aberrant alterations in mitochondrial behaviors and interactions with other organelles. We also review the subsequent impact of mitochondrial changes on cellular functions, such as metabolic reprogramming and the dysregulation of cell death. By presenting a retrospective analysis of previous research and elucidating the underlying mechanisms, we aim to reveal the potential of enhancing the efficacy of chemotherapies and overcoming cancer chemoresistance by targeting mitochondria. Hopefully, this review will provide directions for future research and the development of more viable drugs, ultimately improving the prognosis of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.